- Repairs the structural barrier and improves clinical outcomes 1
- Proven Performance 1,2
- Pleases patients which may improve treatment adherence 1
- Please see Important Safety Information below
Indication: HylatopicPlus® is indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis. HylatopicPlus® also helps to relieve dry, waxy skin by maintaining a moist wound & skin environment, which is beneficial to the healing process. Warnings: HylatopicPlus® is contraindicated in persons with a known hypersensitivity to any component of the formulation. For topical use only. Avoid contact with eyes. If clinical signs of infection are present, appropriate treatment should be initiated; use of HylatopicPlus® may be continued during the anti-infective therapy.
You are encouraged to report adverse effects of prescription drugs and medical devices to the FDA by calling 1-800-FDA-1088 or visiting the website at www.fda.gov/medwatch.
Please see full prescribing information for HylatopicPlus®.
*IMS Xponent, Dec 2012
References 1. Frankel A, Sohn A, Patel RV, Lebwohl MD. Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis. J Drugs Dermatol. 2011;10(6):666-672. 2. Data on file, Onset Dermatologics